Artificial intelligence (AI) encompasses a wide range of methodologies that have been utilized by pharmaceutical corporations over decades, including machine learning, deep learning, and other forms of computational advancements. The development of such advances has opened up unprecedented capabilities of accelerating drug discovery and delivery, increasing treatment regimen optimization, as well as optimizing patient outcomes. AI is revolutionizing the pharmaceutical sector in earnest, altering every aspect ranging from drug discovery and development to precision medicines as target identification and validation, excipient selection, prediction of synthetic route, supply chain optimization, monitoring of continuous manufacturing processes, or predictive maintenance, among others. Although the incorporation of AI has the potential to maximize efficiency, minimize costs, and enhance both medicine and patient health, it nevertheless poses critical issues from a regulatory perspective. In this review article, we will give a holistic overview of AI's applications in the pharma industry, including fields like drug discovery, target optimization, personalized medicine, drug safety, and others. By examining ongoing research patterns and case studies, we seek to enlighten on AI's revolutionary influence on the pharma industry and its broader implications for healthcare
Yash Anil Chaudhari (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: